Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Comparing DADA2 and OTU clustering approaches in studying the bacterial communities of atopic dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early life bacterial airway colonization, local immune mediator response and risk of otitis media

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Danish Whole-Genome-Sequenced Candida albicans and Candida glabrata Samples Fit into Globally Prevalent Clades

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hospital readmissions following infections in dementia: a nationwide and registry-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Waking Up in Pain: a prospective unselected cohort study of pain in 3702 patients immediately after surgery in the Danish Realm

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Beta-hemolytic streptococci A, C and G are susceptible to cloxacillin

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

Vis graf over relationer

Introduction. Cefuroxime is an important antibiotic to treat several serious infections. Rapid elimination through the kidneys and the variation in MICs of various susceptible pathogens such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pneumoniae give rise to dosing issues, especially in otherwise healthy patients. Aim. To investigate the probability of target attainment (PTA) for obtaining the optimal dosage regimens for cefuroxime in healthy young people. Methodology. Two weeks apart 750 and 1500 mg cefuroxime were administered as an intravenous bolus to 20 healthy volunteers (mean age: 27 years). Population modelling and simulation studies were done based on the obtained data for cefuroxime plasma concentration. Results. With a target value of time above MIC (T >MIC) greater than 50% the simulations revealed that a PTA of >99% is obtained for S. pneumoniae with a dosage regimen of 750 mg q12h. For E. coli and K. pneumoniae the PTA was <90% even with the highest, simulated dosage of 1500 mg q6h. For S. aureus a dosage of 1500 mg q8h gave a PTA above 97%. Conclusions. S. pneumoniae is most likely treatable with a two-daily dose of 750 mg cefuroxime. Not treatable are K. pneumoniae and E. coli. For S. aureus 1500 mg q8h constitutes an optimal dosing schedule.

OriginalsprogEngelsk
TidsskriftJournal of Medical Microbiology
Vol/bind69
Udgave nummer3
Sider (fra-til)387-395
Antal sider9
ISSN0022-2615
DOI
StatusUdgivet - mar. 2020

ID: 59662451